Global Nonalcoholic Fatty Liver Disease Clinical Trial Pipeline Highlights 2019-2024 – ResearchAndMarkets.com
June 10, 2019DUBLIN–(BUSINESS WIRE)–The “Global
Nonalcoholic Fatty Liver Disease Clinical Trial Pipeline Highlights –
2019” report has been added to ResearchAndMarkets.com’s
offering.
Nonalcoholic Fatty Liver Disease Pipeline Highlights – 2019, provides
most up-to-date information on key pipeline products in the global
Nonalcoholic Fatty Liver Disease market. It covers emerging therapies
for Nonalcoholic Fatty Liver Disease in active clinical development
stages including early and late stage clinical trials. The pipeline data
presented in this report helps executives for tracking competition,
identifying partners, evaluating opportunities, formulating business
development strategies, and executing in-licensing and out-licensing
deals.
Clinical Trial Stages:
The report provides Nonalcoholic Fatty Liver Disease pipeline products
by clinical trial stages including both early and late stage development
– phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Nonalcoholic Fatty Liver Disease pipeline products
by their dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.
Company:
The report provides Nonalcoholic Fatty Liver Disease pipeline products
by the company.
Short-term Launch Highlights:
Find out which Nonalcoholic Fatty Liver Disease pipeline products will
be launched in the US and Ex-US till 2024.
Summary:
-
Nonalcoholic Fatty Liver Disease phase 3 clinical trial pipeline
products -
Nonalcoholic Fatty Liver Disease phase 2 clinical trial pipeline
products -
Nonalcoholic Fatty Liver Disease phase 1 clinical trial pipeline
products - Nonalcoholic Fatty Liver Disease preclinical research pipeline products
- Nonalcoholic Fatty Liver Disease discovery stage pipeline products
-
Nonalcoholic Fatty Liver Disease pipeline products short-term launch
highlights
Key Topics Covered:
1. Nonalcoholic Fatty Liver Disease Pipeline by Stages
2. Nonalcoholic Fatty Liver Disease Phase 3 Clinical Trial Insights
3. Nonalcoholic Fatty Liver Disease Phase 2 Clinical Trial Insights
4. Nonalcoholic Fatty Liver Disease Phase 1 Clinical Trial Insights
5. Nonalcoholic Fatty Liver Disease Preclinical Research Insights
6. Nonalcoholic Fatty Liver Disease Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/rkjgdh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Liver
and Kidney Disorders Drugs